Efficiency of treatment of adult patients with acute T-lymphoblastic leukemia according to the ALL-2009 protocol of the Russian Acute Leukemia Study Group


Cite item

Full Text

Abstract

AIM: To present the results of treatment in adult patients with acute T-lymphoblastic leukemia (T-ALL) according to the ALL-2009 protocol of the Russian Acute Leukemia Study Group, the basic principle of which is continuation of cytostatic treatment, early switch from prednisolone to dexamethasone, and long-term use of L-asparaginase/MATERIAL AND METHODS: The results of diagnosis and treatment were analyzed in 70 patients with different immunological variants of T-ALL treated in the Russian multicenter trial/RESULTS: Out of the 70 patients with T-ALL, its early immunotype was determined in 32 (45.7%) cases, the thymic and mature immunotypes were found in 31 (44.3%) and 7 (10%) cases, respectively. The median age of the patients with T-ALL was 28 (ranged from 15 to 54) years; men were twice more than women (48 and 22, respectively). Bone marrow lesion was noted in all the patients with early T-ALL and in 80% of the patients with thymic and mature T-ALL. The enlarged mediastinum was significantly more frequently detected in mature T-ALL (100%) than in its early (53.4%) and thymic (60.7%) variants. Therapeutic effectiveness was evaluated in 58 patients. An analysis was made in January 2013. Induction therapy resulted in complete remission in 49 (84.5%) patients. The refractory course of the disease was recorded in 5 (8.6%) cases; early death was in 4 (6.9%). The rate of complete remission in thymic T-ALL, unlike in the early (72%) and mature (71.4%) variants, was significantly higher (100%) due to the absence of resistant forms and early mortality. Moreover, it should be noted that only the patients with early T-ALL (16%) died during the induction phase. In the patients with different variants of T-ALL, the overall and relapse-free survival rates were not significantly different, accounting for 67.2 and 76.2%, respectively. Multivariate analysis revealed no prognostically unfavorable factors that determined long-term results/CONCLUSION: The ALL-2009 protocol is reproducible in any regions of the Russian Federation and highly efficient in treating patients with T-ALL.

About the authors

E N Parovichnikova

ГНЦ Минздрава России, Москва

Email: elenap@blood.ru

G A Kliasova

ГНЦ Минздрава России, Москва

V V Troitskaia

ГНЦ Минздрава России, Москва

A N Sokolov

ГНЦ Минздрава России, Москва

L A Kuz'mina

ГНЦ Минздрава России, Москва

L P Mendeleeva

ГНЦ Минздрава России, Москва

S K Kravchenko

ГНЦ Минздрава России, Москва

V V Ryzhko

ГНЦ Минздрава России, Москва

S N Bondarenko

СПбГМУ им. И.П. Павлова

E A Kariakina

ГКБ №15, СПб

O Iu Baranova

РОНЦ им. Н.Н. Блохина РАМН, Москва

V A Lapin

ОКБ, Ярославль

T V Ryl'tsova

ОКБ, Тула

L V Gavrilova

ОКБ, Саранск

A S Pristupa

ОКБ, Рязань

T S Kaporskaia

ОКБ, Иркутск

T P Zagoskina

НИИГПК, Киров

O S Samoĭlova

ОКБ, Новгород

A V Klimovich

ГКБ №31, СПб

T S Konstantinova

ОКБ, Екатеринбург

N A Vopilina

ОКБ, Тамбов

O P Skamorina

ЦГ ФСБ, Москва

K D Kaplanov

ООД, Волгоград

E E Zinina

ОКБ, Сургут

E V Domracheva

ГНЦ Минздрава России, Москва

I V Gal'tseva

ГНЦ Минздрава России, Москва

S M Kulikov

ГНЦ Минздрава России, Москва

V G Savchenko

ГНЦ Минздрава России, Москва

References

  1. Silverman L.B., Gelber R., Sallan S.E. et al. Improved outcomes for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-1218.
  2. Goldberg J.M., Silverman L.B., Levy D.E. et al. Childhood T-Cell Acute Lymphoblastic leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience JCO 2003; 21 (19): 3616-3622.
  3. Larson R.A., Dodge R.K., Burns C.P. et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85 (8): 2025-2037.
  4. Hoelzer D., Thiel E., Arnold R. et al. Successful Subtype Oriented Treatment Strategies in Adult T-All; Results of 744 Patients Treated in Three Consecutive GMALL Studies. Blood (ASH Annual Meeting Abstracts) 2009; 114: 324.
  5. Marks D.I., Paietta E.M., Moorman A.V. et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009; 114: 5136-5145.
  6. Паровичникова Е.Н., Клясова Г.А., Исаев В.Г. и др. Первые итоги терапии Ph-негативных острых лимфобластных лейкозов взрослых по протоколу Научно-исследовательской группы гематологических центров России ОЛЛ-2009. Тер арх 2011; 7: 11-17.
  7. Parovichnikova E., Davidyan Y., Kliasova G. et al. Absence of Chromosomal Abnormalities Corresponds to Better Survival in Adult Ph-Negative ACUTE Lymphoblastic Leukemia - Results of the Russian ACUTE Lymphoblastic Leukemia (RALL) Study Group. Blood (ASH Annual Meeting Abstracts) 2012; 120: 2572.
  8. SAS Institute Inc. 2004. SAS® 9.1.3, Cary, NC: SAS Institute Inc.
  9. Vitale A., Guarini A., Ariola C. et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006; 107 (2): 473-479.
  10. Pui C.H., Mullighan C.G., Evans W.E., Relling M.V. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012; 120: 1165-1174.
  11. Coustan-Smith Е., Mullighan C.G., Onciu M. et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia Lancet Oncol 2009; 10: 147-156.
  12. Neumann M., Heesch S., Gökbuget N. et al. Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J 2012; 12: e55. doi: 10.1038/bcj.2011.49; published online 27 January 2012

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies